Publication

Use of acridinium-based photocatalyst in the Giese-type coupling of arylboronic acids with electron poor olefins

Caldarelli M, Loriz L, Piazza L, Caputo G, DeAmici M, Papeo G

Tetrahedron Letters (2022) 103, 153978

Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Casuscelli F, Ardini E, Avanzi N, Badari A, Casale E, Disingrini T, Donati D, Ermoli A, Felder E, Galvani A, Isacchi A, Menichincheri M, Montemartini M, Orrenius C, Piutti C, Salom B, Papeo G

Chirality (2022), 34(11), 1437-1452

BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo.

Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J

Cytotherapy (2022), 24(2), 161-171

A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas

Vannata B, Vanazzi A, Negri  M, Liptrott SJ, Bartosek  A , Miani  M , Di Sanzo  A, Cavalli  F, Zucca  E, Stathis A

Hematol Oncol (2021), 39(1), 60-65.

Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes

Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M

ACS Appl Bio Mater (2021), 15, 4(11), 7800-7810

The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene. 

Fugazza C, Barbarani G, Elangovan S, Marini MG, Giolitto S, Font-Monclus I, Marongiu MF, Manunza L, Strouboulis J, Cantù C, Gasparri F, Barabino SML, Nakamura Y, Ottolenghi S, Moi P, Ronchi AE. 

Haematologica (2021), 106(2), 474-482

PHA-680626 Is an effective inhibitor of the interaction between Aurora-A and N-Myc.

Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A

Int J Mol Sci (2021), 22(23), 13122

RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis

La Ferlita A, Alaimo S, Di Bella S, Martorana E, Laliotis G, Bertoni F, Cascione L, Tsichlis P, Ferro A, Bosotti R, Pulvirenti A

BMC Bioinformatics (2021), volume 22, Article number: 298

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S, Sala GL

Pharmaceutics (2021), 13(4), 483

Identification of unprecedented ATP-competitive choline kinase inhibitors

Quartieri F, Nesi M, Avanzi N,  Borghi D, Casale E, Corti  E, Cucchi  U, Donati D,  Fasolini M, Felder  E, Galvani A, Giorgini  ML, Lomolino  A, Menichincheri  M,  Orrenius  C, Perrera  C, Re Depaolini  S, Riccardi-Sirtori F, Salsi E,  Isacchi  A,  Gnocchi  P

Bioorg Med Chem Lett (2021), 51, 128310

A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.

Vannata B, Vanazzi A, Negri M, Liptrott SJ, Bartosek AA, Miani M, Di Sanzo A, Cavalli F, Zucca E, Stathis A.

Hematol Oncol. 2020 Oct 26. doi: 10.1002/hon.2822. Epub ahead of print. PMID: 33103778.

–

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies.

Ardini E, Siena S.

ESMO Open. 2020 Sep;5(5):e000867. doi: 10.1136/esmoopen-2020-000867. PMID: 32907817; PMCID:PMC7481078.

–

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.

Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B, Pungolino E, Elena C, Bergamaschi M, Assouline S, Di Bona E, Gozzini A, Andrade-Campos M, Stagno F, Iurlo A, Pirola A, Fontana D, Petiti J, Bonanomi ML, Crivori P, Piazza R, Fava C, Gambacorti-Passerini C.

Blood. 2020 Nov 5;136(19):2237-2240. doi: 10.1182/blood.2019004371. PMID: 32518953.

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515
Gianluca Papeo,* Paolo Orsini, Nilla R. Avanzi, Daniela Borghi, Elena Casale, Marina Ciomei,
Alessandra Cirla, Viviana Desperati,† Daniele Donati, Eduard R. Felder, Arturo Galvani, Marco Guanci,‡
Antonella Isacchi, Helena Posteri, Sonia Rainoldi, Federico Riccardi-Sirtori,§ Alessandra Scolaro,∥
and Alessia Montagnoli
ACS Medicinal Chemistry Letters 2019

–

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
Sano R, Krytska K, Larmour CE, Raman P, Martinez D, Ligon GF, Lillquist JS, Cucchi U, Orsini P, Rizzi S, Pawel BR, Alvarado D, Mossé YP
Sci Transl Med (2019), 11(483)

–

Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate.
Raposo Moreira Dias A, Pina A, Dean A, Lerchen HG, Caruso M, Gasparri F, Fraietta I, Troiani S, Arosio D, Belvisi L, Pignataro L, Dal Corso A, Gennari C
Chemistry (2019), 25(7), 1696-1700

–

A benchmarking of pipelines for detecting ncRNAs from RNA-Seq data
Di Bella S, La Ferlita A, Carapezza G, Alaimo S, Isacchi A, Ferro A, Pulvirenti A, Bosotti R.
Brief Bioinform (2019), Nov 18 [Epub ahead of print]

–

Investigating miRNA-IncRNA interactions: Computational tools and resources
Veneziano D, Marceca GP, Di Bella S, Nigita G, Distefano R, Croce CM
Methods Mol Biol (2019), 1970 (Chapt 14), 251-277

–

Drug-Initiated synthesis of heterotelechelic polymer prodrug nanoparticles for in vivo imaging and cancer cell targeting
Vinciguerra D, Degrassi A, Mancini L, Mura S, Mougin J, Couvreur P, Nicolas J
Biomacromolecules (2019), 20(7), 2464-2476

–

Mechanism of action of the tumor vessel targeting agent NGR-hTNF: Role of both NGR peptide and hTNF in cell binding and signaling
Valentinis B, Porcellini S, Asperti C, Cota M, Zhou D, Di Matteo P, Garau G, Zucchelli C, Avanzi NR, Rizzardi GP, Degano M, Musco G, Traversari C
Int J Mol Sci (2019), 20(18), 4511-4533